Donepezil in vascular dementia: A randomized, placebo-controlled study

Neurology

Volumn 61, Issue 4, 2003, Pages 479-486

  Wilkinson, David ^a   Doody, R ^b   Helme, R ^c   Taubman, K ^d   Mintzer, J ^e   Kertesz, A ^f   Pratt, R D ^g  

^a MOORGREEN HOSPITAL   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^d AUSTIN HEALTH   (Australia)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANGINA PECTORIS; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; BRAIN FUNCTION; CLINICAL TRIAL; COGNITION; COLITIS; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FRACTURE; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIINFARCT DEMENTIA; NAUSEA; NIGHTMARE; PAIN; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RHINITIS; SKIN ABRASION; SKIN CANCER; STROKE; SYNCOPE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; VERTIGO; VOMITING;

EID: 0042432057     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000078943.50032.FC     Document Type: Article

References (33)

1. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S4-S9.
2. Ebly EM, Parhad IM, Hogan DB, Fung TS. Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology 1994;44:1593-1600.
3. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam Study. BMJ 1995;310:970-973.
4. Desmond DW, Moroney JT, Sano M, Stern Y. Mortality in patients with dementia after ischemic stroke. Neurology 2002;59:537-543.
5. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-1166.
6. Togashi H, Kimura S, Matsumoto M, Yoshioka M, Minami M, Saito H. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke 1996;27:520-525.
7. Kimura S, Saito H, Minami M, et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000;153:167-178.
8. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996;103:1211-1220.
9. Swartz RH, Black SE. How common is vascular compromise of cholinergic white matter pathways in a memory clinic sample? J Neurol Sci 2002;203-204:281.
10. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-1459.
11. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-1290.
12. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145.
13. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-244.
14. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495.
15. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled, preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488.
16. Mendez MF, Younesi FL, Perryman KM. Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999;11:268-270.
17. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
18. Folstein MF, Folstein FE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926.
20. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
21. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI). A clinician's global rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321.
22. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:S22-S32.
23. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988;24:637-639.
24. Gauthier S, Ferris S. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease. Int J Clin Pract suppl 2001;120:29-39.
25. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-1031.
26. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.
27. Pratt RD. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J Neurol Sci 2002;203-204:57-65.
28. Sachdev PS, Brodaty H, Looi JC. Vascular dementia: diagnosis, management and possible prevention. Med J Aust 1999;170:81-85.
29. Kittner B, De Deyn PP, Erkinjuntti T. Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials. Ann NY Acad Sci 2000;903:535-541.
30. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834-1839.
31. Padovani A, Di Piero V, Bragoni M, Iacoboni M, Gualdi GF, Lenzi GL. Patterns of neuropsychological impairment in mild dementia: a comparison between Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 1995;92:433-442.
32. Perdomo C, Pratt R. A comparison of the effects of donepezil in patients with probable and possible vascular dementia: a combined analysis of two 24-week, randomized, double-blind, placebo-controlled trials. Neurology 2002;58(suppl 3):PO5.115.
33. Pratt RD, Perdomo CA, Surick IW, Ieni JR. Donepezil: tolerability and safety in Alzheimer's disease. Int J Clin Pract 2002;56:710-717.